drugset / Trial / NCT06289452
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
Phase 0
Active not recruiting
18 enrolled
InnoVec Biotherapeutics Inc.
Peking Union Medical College Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.
Timeline
- Start
- 2024-03-08
- Primary completion
- 2025-12-31
- Completion
- 2029-12-31
Publications
- Background Pimenides D, George ND, Yates JR, Bradshaw K, Roberts SA, Moore AT, Trump D. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005 Jun;42(6):e35. doi: 10.1136/jmg.2004.029769.
- Background Wang XF, Chen FF, Zhou X, Cheng XX, Xie ZG. A novel mutation in RS1 and clinical manifestations in a Chinese twin family with congenital retinoschisis. Front Genet. 2022 Sep 23;13:993157. doi: 10.3389/fgene.2022.993157. eCollection 2022.
- Background Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007 Apr;44(4):225-32. doi: 10.1136/jmg.2006.047340. Epub 2006 Dec 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IVB102 | Gene therapy (AAV / viral vector) | — | Intravitreal |